Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients

D. Zanon, U. M. Musazzi, A. Manca, A. De Nicolò, A. D'Avolio, F. Cilurzo, N. Maximova, C. Tomasello, E. Clementi, P. Minghetti

Research output: Contribution to journalArticlepeer-review


The COVID-19 outbreak is now one of the most critical crises to manage for most of national healthcare systems in the world. The situation is complicated by the absence of vaccines and authorized pharmacological treatments, except for remdesivir. In this context, many medicaments, including different Ebola and HIV antivirals, are used off-label in the hospital wards as life-treating medicines for COVID-19 patients. Authorized medicaments manipulation is sometimes necessary because they are not always formulated to be administered to non-cooperative patients or they are in shortage. It is this the case of the fixed combination of lopinavir/ritonavir, which was extensively used in the first phase of the outbreak inducing a shortage of the oral solution available in the EU market. This work provides data on size distribution, osmolarity other than drug chemical stability of a lopinavir/ritonavir extemporaneous preparation made by using the solid dosage form (i.e., tablet) available on the market as drug source. The reported data indicate that such preparation is suitable to be delivered through a nasogastric tube, and enough stable for two weeks from the preparation at room temperature.

Original languageEnglish
Article number106445
JournalData in Brief
Publication statusPublished - Dec 2020


  • COVID-19
  • Lopinavir
  • Medicament manipulation
  • Nasogastric tube
  • Osmolarity
  • Particle size distribution
  • Ritonavir

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients'. Together they form a unique fingerprint.

Cite this